Floatz logo

Tilmanocept

Sentinel Lymph Node Biopsy

Memorial Health University Medical CenterOtherPhase 4 / ApprovedDormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Sentinel Lymph Node Biopsy cohort.

Asset / SponsorPhaseRating
TECHNETIUM TC 99M SULFUR COLLOID
Novadaq Technologies ULC, now a part of Stryker
Phase 4BB
IC2000
Novadaq Technologies ULC, now a part of Stryker
Phase 3BB
Pudexacianinium Chloride
Astellas Pharma Inc
Phase 2CCC
MIDAZOLAM
Jun Zhang
N/AD
PROPOFOL
Jun Zhang
N/AD

View all 9 →

Same molecule, other indications

Tilmanocept is also rated in:

melanomaDormant
B
Indicative ·
61 / 100
View asset →
Sentinel Lymph NodeDormant
B
Indicative ·
56 / 100
View asset →
head and neck cancerDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →